Table 1

Baseline patient characteristics

No. of patients, N = 869% of patientsMedian (IQR)
Age, y74 (70-78)
 ≤65162
 65-7445152
 ≥7540246
 ≥8016119
Creatinine, mg/dL0.98 (0.80-1.22)
 <280292
 ≥2375
 Missing303
ECOG PS
 025830
 139846
 216619
 3142
ISS
 I23928
 II36142
 III26931
Chromosome abnormalities
 t(4;14)809
 t(14;16)223
 del17p1310512
 Missing14717
 Unfavorable profile32938
ADL6 (5-6)
 >475086
 ≤411914
IADL8 (6-8)
 >571382
 ≤515618
CCI0 (0-1)
 ≤172583
 ≥214417
Therapy
 Lenalidomide-containing regimens65976
 Proteasome inhibitor-containing regimens21024
  • Unfavorable profile defined as t(4;14) or t(14;16) or del17p13.

  • ADL, Activity of Daily Living; CCI, Charlson Comorbidity Index; ECOG PS, Eastern Cooperative Oncology Group performance status; IADL, Instrumental Activity of Daily Living; IQR, interquartile range; ISS, International Staging System.